|1.||Hasegawa, Chika: 1 article (12/2006)|
|2.||Suzuki, Osamu: 1 article (12/2006)|
|3.||Kumazawa, Takeshi: 1 article (12/2006)|
|4.||Lee, Xiao-Pen: 1 article (12/2006)|
|5.||Sato, Keizo: 1 article (12/2006)|
|6.||Kuriki, Ayako: 1 article (12/2006)|
|7.||Kawamura, Mitsuru: 1 article (12/2006)|
|8.||Katsuki, Hiroshi: 1 article (01/2003)|
|9.||Muraoka, Shizuko: 1 article (01/2003)|
|10.||Takahata, Kazue: 1 article (01/2003)|
|1.||Parkinson Disease (Parkinson's Disease)
12/05/2006 - "The determination of selegiline and desmethylselegiline concentrations in Parkinson's disease patients undergoing continuous selegiline treatment is presented and is shown to validate the present methodology."
01/01/2003 - "Selegiline, a therapeutic agent of Parkinson's disease, and its metabolite, desmethylselegiline, were explored for their neuroprotective effects against N-methyl-D-aspartate (NMDA)-induced cell death in rat retina. "
01/01/1999 - "Deprenyl, a monoamine oxidase inhibitor used in the treatment of Parkinson's disease, along with its primary metabolite desmethyldeprenyl (DES) have been shown to reduce neuronal apoptosis by a mechanism that requires gene transcription and involves the maintenance of mitochondrial membrane potential. "
07/01/1997 - "Desmethylselegiline is an orally active, irreversible inhibitor of MAO-B and could possibly be used to treat Parkinson's disease in the same way as selegiline."
|2.||Neurodegenerative Diseases (Neurodegenerative Disease)
05/01/2000 - "The rationale is, in part, based on an observation that desmethyldeprenyl exerts antiapoptotic activities in a variety of neurodegenerative disorders. "
12/01/1996 - "If apoptosis is critical to the progression of one or more human neurodegenerative diseases, then transcriptionally active agents such as (-)-desmethyldeprenyl may be of value in treating the diseases. "
|3.||Monoamine Oxidase Inhibitors (Monoamine Oxidase Inhibitor)
|4.||Monoamine Oxidase (MAO)